Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage I-III breast cancer~* Scheduled to undergo treatment with doxorubicin-based chemotherapy regimen~* Able to provide informed consent~Exclusion Criteria:~* Use of anthracycline agents other than doxorubicin~* Baseline LVEF ≤50% by any modality (nuclear, echo, MRI)~* Atrial fibrillation or flutter~* Mitral valve disease (More than mild mitral stenosis or regurgitation, previous mitral valve replacement or repair)~* Inability to obtain adequate echo images for required analysis~* Hyperkalemia (K+ \>5.0)~* Glomerular filtration rate (GFR) \<30 ml/min/1.73m2~* Uncontrolled hypertension, defined as having a systolic blood pressure \> 180 mmHg and/or a diastolic blood pressure \>110 mmHg~* Symptomatic hypotension or systolic blood pressure \<85 mmHg~* History of hypersensitivity to eplerenone or spironolactone~* Significant hepatic disease (e.g., previously documented positive serology for viral hepatitis) or aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \>3 times the upper limits of normal~* Concomitant treatment with spironolactone, potassium-sparing diuretics, potassium supplements, or strong inhibitors of cytochrome P450 3A4 (CYP3A4) (i.e. ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir)~* History of alcohol and/or any other drug abuse~* Women who are either pregnant, lactating or of childbearing potential and not using an acceptable method of contraception~* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): One tablet by mouth daily. If serum potassium level is \<5.0 mmol/L at four weeks, increase to two tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: one tablet by mouth every other day. If serum potassium level is \<5.0 mmol/L at four weeks, increase to one tablet by mouth daily.
- Eplerenone (Type: EXPERIMENTAL): Eplerenone 25 mg tablet by mouth daily. If serum potassium level is \<5.0 mmol/L at four weeks, increase to two 25 mg tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: eplerenone 25 mg tablet by mouth every other day. If serum potassium level is \<5.0 mmol/L at four weeks, increase to 25 mg tablet by mouth daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).